Description
The DPYD Screen test is a genetic test designed to help reduce severe toxic, adverse events and improve treatment outcomes. For cancer patients undergoing therapy with fluoropyrimidine drugs like Fluorouracil (5-FU) and Capecitabine this test may be particularly important.
These medications are commonly used in the treatment of various cancers but can also lead to serious side effects, including myelosuppression. In some cases, these adverse events can be fatal, affecting up to one percent of patients receiving these treatments.
